Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Down 40.3% in March

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 4,300 shares, a decline of 40.3% from the February 28th total of 7,200 shares. Based on an average trading volume of 8,000 shares, the short-interest ratio is currently 0.5 days. Currently, 0.0% of the company’s shares are sold short.

Adlai Nortye Trading Down 11.0 %

Shares of NASDAQ ANL opened at $1.94 on Friday. The stock has a 50 day moving average price of $2.20 and a 200 day moving average price of $2.22. Adlai Nortye has a 52-week low of $1.85 and a 52-week high of $17.48.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.